The effects of a protein kinase C beta inhibitor, LY333531 [ruboxistaurin], on vascular and neural functions in type 2 diabetes mellitus - study B7A-MC-MBDM

Trial Profile

The effects of a protein kinase C beta inhibitor, LY333531 [ruboxistaurin], on vascular and neural functions in type 2 diabetes mellitus - study B7A-MC-MBDM

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Ruboxistaurin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top